Citizens JMP raised the firm’s price target on Aquestive Therapeutics (AQST) to $12 from $9 and keeps an Outperform rating on the shares. Aquestive announced the issuance of two additional patents for Anaphylm, extending brand exclusivity through at least 2037, the analyst tells investors in a research note. The patents are meaningfully value accretive as they cover compositions of matter for the novel epinephrine prodrug used in the product candidate, the firm says.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics Secures New Patents for Anaphylm
- Aquestive Therapeutics issued two additional U.S. patents to Anaphylm
- Aquestive Therapeutics Advances Anaphylm Clinical Development
- Aquestive, Veeva, Oklo, BioMarin, TKO: Trending by Analysts
- Aquestive Therapeutics Highlights at Global Investor Conference